SCHEMBL10150253

SCHEMBL10150253

Cc1cc(C)c2c(c1)CC(=NOCc1ccc([N+](=O)[O-])cc1)/C=C/CC/C=C/CC(C)OC2=O

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.35
MKNK2 Q9HBH9 1/20 0.34
HSP90AB1 P08238 1/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 2/20 0.31
GAA P10253 1/20 0.31
HTT P42858 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
F13A1 P00488 1/20 0.30
TGM2 P21980 1/20 0.30
MAOB P27338 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150196 0.89 MKNK2 (0.38) MAOAMKNK2HSP90AB1F13A1TGM2
SCHEMBL10150278 0.87 MKNK2 (0.46) MKNK2HSP90AB1ALDH1A1CYP3A4SMN1; SMN2
SCHEMBL10150233 0.83 HSP90AB1 (0.40) MAOAMKNK2HSP90AB1F13A1TGM2
SCHEMBL13049834 0.80 HSP90AB1 (0.41) MAOAMKNK2HSP90AB1F13A1TGM2
SCHEMBL10150295 0.80
SCHEMBL10150229 0.80 HSP90AB1 (0.42) MAOAMKNK2HSP90AB1F13A1TGM2
SCHEMBL10150250 0.80 HSP90AB1 (0.40) MAOAMKNK2HSP90AB1F13A1TGM2
SCHEMBL10150857 0.77 HSP90AB1 (0.46) MAOAMKNK2HSP90AB1F13A1TGM2
SCHEMBL10150189 0.77 HSP90AB1 (0.46) MAOAMKNK2HSP90AB1F13A1TGM2
SCHEMBL10150877 0.76 MKNK2 (0.47) MAOAMKNK2HSP90AB1F13A1TGM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450305-B2 Macrocyclic compounds useful as inhibitors of kinases and HSP90 UNIVERSITE DE STRASBOURG (FR) 2013-05-28 US disclosed
US-8329683-B2 Treatment of neurofibromatosis with radicicol and its derivatives NEXGENIX PHARMACEUTICALS, LLC (US) 2012-12-11 US disclosed
US-20120077775-A1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-03-29 US disclosed
US-8067412-B2 analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen UNIVERSITE DE STRASBOURG (FR) 2011-11-29 US disclosed
US-20100292218-A1 Treatment Of Neurofibromatosis With Radicicol And Its Derivatives NEXGENIX PHARMACEUTICALS HOLDINGS, INC. 2010-11-18 US disclosed
US-20080146545-A1 Macrocyclic compounds useful as inhibitors of kinases and HSP90 UNIVERSITE DE STRASBOURG (FR) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077775-A1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 HSP90AB1, HSP90AA1, HSP90AB2P MAOA 3967/4885MKNK2 12/4885HSP90AB1 1/4885
US-20100292218-A1 Treatment Of Neurofibromatosis With Radicicol And Its Derivatives HSP90AB2P, HSP90AA1, HSPA2 MAOA 3279/4885MKNK2 2172/4885HSP90AB1 4/4885
US-20080146545-A1 Macrocyclic compounds useful as inhibitors of kinases and HSP90 HSP90AB1, HSP90AA1, HSP90AB2P MAOA 3967/4885MKNK2 12/4885HSP90AB1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.